Skip to main content
SpringerLink
Log in

Lipidsenkende Mittel

  • Chapter
Arzneiverordnungs-Report 2017

  • 2088 Accesses

Zusammenfassung

Erhöhte Cholesterinwerte des Low-Density-Lipoprotein (LDL)-Cholesterins gehören zusammen mit arterieller Hypertonie, Diabetes mellitus und Zigarettenkonsum zu den wichtigsten Risikofaktoren kardiovaskulärer Krankheiten. Ein aktuelles Konsensus-Statement der European Atherosclerosis ociety begründet anhand der Evidenz aus genetischen, epidemiologischen und klinischen Studien die kausale Rolle LDL- Cholesterins für Atherosklerose bedingte kardiovaskuläre Erkrankungen (Ference et al. 2017). Zur therapeutischen Evidenz gehören die Metaanalysen der Cholesterol Treatment Trialists Collaborators (CTT), die eine 21% relative Risikoreduktion kardiovaskulärer Ereignisse pro 1 mmol/l LDL-C- Senkung ergaben (Cholesterol Treatment Trialists Collaborators 2005).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bundesministerium für Gesundheit (2016a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Evolocumab vom 9. März 2016, veröffentlicht am Montag, 4. April 2016 BAnz AT 04.04.2016 B6

    Google Scholar 

  • Bundesministerium für Gesundheit (2016b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Alirocumab

    Google Scholar 

  • Bundesministerium für Gesundheit (2016c): Bekanntmachung des Gemeinsamen Bundesausschusses gemäß § 91 des Fünften Buches Sozialgesetzbuch (SGB V) vom 26. April 2016, Stellungnahmeverfahren zur Änderung der Arzneimittel-Richtlinie Anlage III – Übersicht über Verordnungseinschränkungen und –ausschlüsse Alirocumab, veröffentlicht am Freitag, 6. Mai 2016 BAnz AT 06.05.2016 B2

    Google Scholar 

  • Bundesministerium für Gesundheit (2016d): Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht über Verordnungseinschränkungen und –ausschlüsse Evolocumab vom 2. Juni 2016 veröffentlicht vom 2. Juni 2016 veröffentlicht am Freitag, 12. August 2016 BAnz AT 12.08.2016 B1

    Google Scholar 

  • Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators (2015): Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015 Jun 3. [Epub ahead of print]

    Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators (2005): Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278

    Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681

    Google Scholar 

  • Cholesterol Treatment Trialists’ Collaboration (2015): Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385: 1397–1405

    Google Scholar 

  • Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL (2016): 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 37(39):2999-3058

    Google Scholar 

  • De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99: 779–785

    Google Scholar 

  • De Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, Uleryk E, Budylowski P, Schünemann H, Beyene J, Anand SS (2015): Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015 Aug 11;351:h3978. doi: 10.1136/bmj.h3978

    Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (2011): ESC/EAS/DGK Pocket-Leitlinien: Diagnostik und Therapie der Dyslipidämien. Internet: http://leitlinien.dgk.org/images/pdf/leitlinien_pocket/2012_pll_25_dys.pdf

  • Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators (2013): Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368: 1279–1290

    Google Scholar 

  • Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL (2017): Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Apr 24. doi: 10.1093/eurheartj/ehx144

    Google Scholar 

  • Gemeinsamer Bundesausschuss (2016): Mündliche Anhörung gemäß 5. Kapitel § 19 Abs. 2 Verfahrensordnung des Gemeinsamen Bundesausschusses, hier: Alirocumab, Sitzung im Hause des Gemeinsamen Bundesausschusses in Berlin am 22. März 2016 von 11:30 Uhr bis 13:12 Uhr –Stenografisches Wortprotokoll. Internet: https://www.g-ba.de/informationen/nutzenbewertung/199/#tab/stellungnahmeverfahren

  • Heart Protection Study Collaborative Group (2011): C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469–476

    Google Scholar 

  • HPS2-THRIVE Collaborative Group (2013): HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: 1279–1291

    Google Scholar 

  • Jun M, Foote C, Lv L, Neal B, Patel A, Nicholls S, Grobbee DE, Cass A, Chalmers A, Perkovic V (2010): Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875–1884

    Google Scholar 

  • Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Merkel M, Müller-Wieland D, Noll G, Parhofer KG, Paulweber B, Riesen W, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E (2014): Neue AHA- und ACC-Leitlinie zur Risikoreduktion von Herz-Kreislauf-Erkrankungen durch Cholesterinsenkung, Stellungnahme der D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V., der Österreichischen Atherosklerose Gesellschaft und der Arbeitsgruppe Lipide und Atherosklerose (AGLA) der Schweizer Gesellschaft für Kardiologie. Internist 55: 601–606

    Google Scholar 

  • Libby P (2013): Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 368: 2004–2013

    Google Scholar 

  • Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 351–364, 365–374

    Google Scholar 

  • Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G (2016): Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 37: 3588–3595

    Google Scholar 

  • National Institute for Heath and Care Excellence (2016a): Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance. Published: 22 June 2016. Internet: nice.org.uk/guidance/ta394

    Google Scholar 

  • National Institute for Heath and Care Excellence (2016b): Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance. Published: 22 June 2016. Internet: nice.org.uk/guidance/ta393

    Google Scholar 

  • Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL (2013): Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61: 404–410

    Google Scholar 

  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al.; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators (2005): Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38

    Google Scholar 

  • Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; RUTHERFORD-2 Investigators (2015a): PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385: 331–340

    Google Scholar 

  • Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators (2015b): Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385: 341–350

    Google Scholar 

  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators (2005): C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28

    Google Scholar 

  • Ridker PM (2014): LDL cholesterol: controversies and future therapeutic directions. Lancet 384: 607–617

    Google Scholar 

  • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators (2015): Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489–1499

    Google Scholar 

  • Robinson JG, Stone NJ (2015): The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J 2015 May 20. pii: ehv182. [Epub ahead of print]

    Google Scholar 

  • Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators (2008): N Engl J Med 359: 1343–1356

    Google Scholar 

  • Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators (2017): Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376: 1713–1722

    Google Scholar 

  • Schönbeck U, Libby P (2004): Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 (Suppl II): II 18–26

    Google Scholar 

  • Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators (2012): Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099

    Google Scholar 

  • Shepherd J (2002): Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 359: 2271–2273

    Google Scholar 

  • Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW (2013): 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12. [Epub ahead of print]

    Google Scholar 

  • The ACCORD Study Group (2010): Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574

    Google Scholar 

  • The AIM-HIGH Investigators (2011): Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255–2267

    Google Scholar 

  • The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102: 21–27

    Google Scholar 

  • The FIELD study investigators (2005): Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861

    Google Scholar 

  • The STABILITY Investigators (2014): Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med 370: 1702–1711

    Google Scholar 

  • The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011): ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32: 1769–818

    Google Scholar 

  • Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61 (Sonderheft 2): S72–S78

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gemeinschaftspraxis Dres. Thomas Beckenbauer und Stefan Maierhof, Am Markt 11, 28195, Bremen, Deutschland

    Gerald Klose

  2. Pharmakologisches Institut der, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

Authors
  1. Gerald Klose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald Klose .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Klose, G., Schwabe, U. (2017). Lipidsenkende Mittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation